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Abstract
 
One major objective of tumor immunologists is to prevent cancer development in individuals
 
at high risk. (TG.AC 
 
3 
 
C57BL/6)F1 mice serve as a model for testing the feasibility of this ob-
jective. The mice carry in the germline a mutant ras oncogene that has an arginine at codon 12
instead of glycine present in the wild-type, and after physical (wounding) or chemical promo-
tion, these mice have a high probability for developing papillomas that progress to cancer. Fur-
 
thermore, F1 mice immunized with Arg
 
12
 
 mutant ras peptide in complete Freund’s adjuvant
(CFA) develop T cells within 10 d that proliferate in vitro on stimulation with the Arg
 
12
 
 mu-
tant ras peptide. Within 14 d, these mice have delayed-type hypersensitivity to the peptide.
Immunization with CFA alone or with a different Arg
 
12
 
 mutant ras peptide in CFA induced
neither response. To determine the effect of immunization on development of tumors, mice
immunized 3 wk earlier were painted on the back with phorbol 12-myristate 13-acetate every
3 d for 8 wk. The time of appearance and the number of papillomas were about the same in
immunized and control mice, but the tumors grew faster and became much larger in the mice
immunized with the Arg
 
12
 
 mutant ras peptide. Thus, the immunization failed to protect against
 
growth of papillomas. The peptide-induced CD4
 
1
 
 T cells preferentially recognized the peptide
but not the native mutant ras protein. On the other hand, mice immunized with Arg
 
12
 
 mutant
ras peptide and bearing papillomas had serum antibodies that did bind native mutant ras pro-
tein. Together, these studies indicate that active immunization of cancer-prone individuals may
result in immune responses that fail to eradicate mutant oncogene–expressing tumor cells, but
rather induce a remarkable enhancement of tumor growth.
Key words: primary tumor • immune stimulation • active immunization • mutant ras gene • 
cancer-prone mice
 
Introduction
 
More than 20 human hereditary cancer syndromes have
been described, and germline mutations that predispose to
development of cancer continue to be discovered (1). Fur-
thermore, during the development of some human cancers,
a predictable set of somatic mutations in known oncogenes
or suppressor genes occurs. Starting from the mutant se-
quence of these genes, candidate peptides have been de-
rived that bind MHC molecules and induce immune re-
sponses. Preimmunization of cancer-prone individuals with
the mutant peptides might prevent the development of
cancers in patients carrying such mutant oncogenes or sup-
pressor genes. To test this possibility, a murine model of a
hereditary cancer syndrome has been developed using mice
that carry the Harvey ras oncogene, which has a glycine-
to-arginine point mutation at codon 12 and an alanine-to-
threonine point mutation at codon 59 (2). Several features
of this model are attractive. As observed in humans, the
mutant oncogene is closely related to the normal cellular
gene in that it differs from the normal cellular homologue
by only two point mutations (3), and the development of
tumors is influenced by nonmutagenic environmental fac-
tors, i.e., tumor development depends on chemical or bio-
logical promotion that by itself is not tumorigenic (2, 4, 5).
The Arg
 
12 
 
mutant ras protein is expressed in papillomas and
cancers that develop in TG.AC mice, but is barely detect-
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able or absent in skin of TG.AC mice, even when the skin
has been exposed repeatedly to chemical promoters (2, 6).
Expression of the mutant protein in the tumor-prone trans-
genic mice seems to be focal and occurs at the time tumors
begin to develop (5–7). This late expression of the mutant
protein should preclude the development of neonatal and/
or peripheral tolerance, whereas the restricted expression
should allow selective immunological destruction of malig-
nant and premalignant foci without destruction of normal
tissues. T cells have been reported to recognize the mutant
oncoprotein (8), and peptides containing the arginine for
glycine amino acid substitution induce highly specific
CD4
 
1
 
 T cell responses (8). Furthermore CD4
 
1
 
 T cells can
destroy MHC class II–negative tumor cells, even in the ab-
sence of CD8
 
1
 
 T cells (9, 10), by an IFN-
 
g
 
–dependent
mechanism (11). As might have been predicted from these
previous observations, we found that cancer-prone mice
immunized with the mutant peptide had highly specific T
cell responses to the peptide, but interestingly and contrary
to expectation, the growth of the tumors in these specifi-
cally immunized mice was markedly enhanced. Our find-
ings provide a cautionary note for investigators intending
to prevent or treat cancers by immunizing patients against
cancer antigens using mutant peptides.
 
Materials and Methods
 
Mice. 
 
6–8-wk-old germ-free–derived specific pathogen-free
C57BL/6 (H-2
 
b
 
) females were purchased from the National Can-
cer Institute, Frederick Cancer Research Facility, and FVB/N
were purchased from Taconic Farms. A stock of specific patho-
gen-free TG.AC mice were obtained in 1995 from the National
Institute of Environmental Health Sciences colony kept at
Taconic Farms. As described previously (2), the TG.AC founders
are of FVB (H-2
 
q
 
) origin and are transgenic for the viral Harvey
ras (vHa-ras)
 
1
 
 oncogene under the control of the 
 
z
 
-globin pro-
moter. The vast majority
 
 
 
(
 
.
 
95%), but not all TG.AC mice, de-
velop multiple mutant ras–expressing papillomas 6–8 wk after
promotion with the phorbol ester PMA (GIBCO BRL Life
Technologies; reference 2). We have carried this line by brother–
sister matings, and these mice continue to develop papillomas at a
 
.
 
95% incidence. Recently, a confounding nonresponder TG.AC
genotype has been described to have arisen in the Taconic Farms
colony (12, 13). The genotype becomes apparent in the hemizy-
gous TG.AC mice (F1 between homozygous TG.AC and the pa-
rental FVB) that were sold by Taconic Farms (12, 13). These
hemizygous nonresponder mice (even though they are homozy-
gous for the promotion-sensitive FVB background) develop no
papillomas (90% of the mice) or only one papilloma (10% of the
mice) upon promotion. We have no evidence that a nonre-
sponder genotype developed in our TG.AC colony, as our hemi-
zygous F1 mice have an up to 100% papilloma response rate when
properly promoted. (TG.AC
 
 3 
 
C57BL/6)F1 (TGB6F1) mice
that carry one allele of the mutant ras transgene and (FVB 
 
3
 
C57BL/6)F1 (FVB6F1) mice were bred and housed in a specific
 
pathogen-free barrier facility at The University of Chicago (14).
C57BL/6 mice are virtually nonresponders to chemical promo-
tion (15). Therefore, the TGB6F1 mice we generated are less sus-
ceptible to tumor induction than homozygous TG.AC mice, in
that with shorter length of promotion some of these mice may
not develop tumors. Though we have no evidence whatsoever
that a nonresponsive genotype was present in our hemizygous
TGB6F1 mice, we have reevaluated our results as though this was
the case, and we find that there is no noticeable difference in the
results (data not shown).
 
Cell Lines.
 
Tumor cell lines were passed in DMEM supple-
mented with glutamine (GIBCO BRL Life Technologies) and
10% FCS (HyClone Laboratories). T cell hybridoma cell lines and
CTLL cells were passed as described (16). An anti-Arg
 
12
 
 mutant
ras peptide–specific T cell line was generated from lymph node
cells (LNCs) obtained from a C57BL/6 mouse immunized with
Arg
 
12
 
 mutant ras peptide in CFA. The LNCs were cultured using
IL-2 and antigen. 4 d after passage, 2 
 
3 
 
10
 
7
 
 T cells and 2 
 
3 
 
10
 
7
 
BW5147 cells were fused as described (16) to generate anti-Arg
 
12
 
ras T cell hybridoma no. 1. A second anti-Arg
 
12
 
 mutant ras pep-
tide–specific CD4
 
1
 
 T cell line has been described as 2F9 (8); T
cells of this line were fused to generate anti-Arg
 
12
 
 ras T cell hybrid-
oma no. 2.
 
Ras Peptides and Proteins. 
 
The wild-type ras peptide con-
sisted of amino acids 5–17 (KLVVVGAGGVGKS). The Arg
 
12
 
mutant ras peptide also consisted of amino acids 5-17 (KLV-
VVGARGVGKS), but had a G to R substitution at codon 12.
The Leu
 
61
 
 mutant ras peptide consisted of amino acids 54–67
(DILDTAGLEEYSAM) and had a Q to L substitution at codon
61. Peptides were obtained from either The University of Chi-
cago Protein Core Facility or from Chiron Mimotopes or SynPep.
Peptides prepared to at least 70% purity as verified by mass spec-
troscopy were resuspended before use in double-distilled H
 
2
 
O to a
final concentration of 10 mg/ml and stored at 
 
2
 
80
 
8
 
C until used.
To generate recombinant ras proteins at highest purity, we de-
veloped a new ras vector using the glutathione 
 
S
 
-transferase
(GST) Gene Fusion System (Amersham Pharmacia Biotech). The
vHa-ras gene was amplified by PCR from the PA9 plasmid (2)
using a 5
 
9
 
 primer containing a BamHI site (CGTGGATCCAT-
GACAGAATACAAGCTTGT) and a 3
 
9
 
 primer containing an
EcoRI site (CGATGAATTCAGGACAGCACACACTTG-
CAGCT). 10-min initial denaturation was followed by 35 cycles
of 55
 
8
 
C annealing (30 sec), 72
 
8
 
C extension (45 sec), and 94
 
8
 
C de-
naturation (30 sec). 600 base pair fragments containing the vHa-
ras gene were amplified, purified using Qiaquick PCR columns
(Qiagen), and cloned into the pGEX-6P-1 vector using the
BamHI and EcoRI restriction sites that in previous studies was
used to generate GST fusion proteins (Amersham Pharmacia Bio-
tech). The fusion protein was prepared and purified according to
the manufacturer’s detailed instructions. In brief, the recombinant
fusion protein made in BL21 strain of 
 
Escherichia coli
 
 was bound to
glutathione Sepharose 4B (Amersham Pharmacia Biotech),
washed three times with large volumes of PBS, and then eluted
with glutathione elution buffer. Free fusion protein was evaluated
by Western blot assay using ras-specific antibodies (17). The fu-
sion protein was subsequently cut with Precision Protease (Amer-
sham Pharmacia Biotech) and repurified with glutathione
Sepharose 4B to remove the GST protein. The Precision Protease
is a GST fusion protein that also binds to glutathione Sepharose
4B. The resulting highly purified recombinant ras protein retains
only five amino acids (GPLGS) of GST. After final purification,
the GST ras tumor protein appears to be 99% pure as assessed by
silver-stained gels. In some experiments, mutant ras protein was
 
1
 
Abbreviations used in this paper:
 
 DTH, delayed-type hypersensitivity;
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3 
 
C57BL/6)F1 hybrid; GST, glutathione 
 
S
 
-transferase;
LNC, lymph node cell; TGB6F1, (TG.AC
 
 3 
 
C57BL/6)F1 hybrid; vHa-
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digested using endoproteinase Glu-C (Boehringer); the protease
was added to a final volume of 2% (vol/vol), and the protein was
digested at 37
 
8
 
C overnight. The enzyme in the mixture was then
inactivated by boiling. As control antigen, the ribosomal protein
L26 was made as a recombinant fusion protein using the same
procedures for purification. After final purification, the GST L26
fusion protein appears to be 
 
.
 
90% pure as assessed by Coomassie
silver-stained gels. All proteins were stored in aliquots at 
 
2
 
80
 
8
 
C.
All mutant ras proteins were stored in aliquots at 
 
2
 
80
 
8
 
C. In some
experiments, we used a recombinant Arg
 
12
 
 ras protein provided
by Dr. R.G. Fenton (National Cancer Institute, Frederick Cancer
Research Facility, Frederick, MD). This protein had been puri-
fied by ion exchange chromatography and gel filtration.
 
Immunizations and Promotion.
 
Each hind footpad of naive ani-
mals was injected with 50–75 
 
m
 
g of the mutant Arg
 
12
 
 ras or the
mutant Leu
 
61
 
 ras peptide (total dose 100–150 
 
m
 
g) emulsified in
CFA. 3 wk after immunization, the backs of mice were shaved
using electric clippers (Wahl Clipper Corp.) without nicking the
skin. 200 
 
m
 
l containing 2.5 
 
m
 
g of PMA in acetone (99.5% pure
ACS spectrometric grade; Sigma-Aldrich) was distributed evenly
over the shaved back using an Eppendorf pipettor and a 200-
 
m
 
l
yellow plastic pipette tip with 2 mm of the tip cut off. PMA was
applied every 3 d for 20 applications. Hair was shaved several
times during promotion as required by hair growth. Individual
papillomas were measured in three orthogonal dimensions with a
caliper. Tumor measurements usually continued for 16–20 wk af-
ter the start of promotion. Tumor volume was estimated by 
 
p
 
 
 
3
 
abc/6, where a, b, and c are three orthogonal tumor diameters re-
corded in millimeters.
 
Proliferation, IL-2 Release, and Delayed-type Hypersensitivity
Assays. 
 
Draining popliteal or paraaortic LNs were harvested 7 d
after immunization. Suspensions of the LNCs were cultured in
duplicate or triplicate with 10
 
6
 
 cells per well in 96-well flat-bot-
tomed plates. Unless otherwise indicated, each culture contained
100
 
 
 
m
 
g/ml antigen and 1% normal mouse serum. Wells were
pulsed on day 2–3 of culture [methyl-
 
3
 
H]thymidine (Amersham
Pharmacia Biotech) as described (16). 24 h later, cells were har-
vested and the radioactivity was measured in a liquid scintillation
counter as described (16). Proliferative responses of the T cell
lines to the antigens were measured by culturing 1–2 
 
3
 
 10
 
5
 
 T
cells, 10
 
6
 
 irradiated syngeneic spleen cells as APCs, and 10 
 
m
 
g/ml
of Arg
 
12
 
 mutant ras peptide for 2–3 d, pulsing with 
 
3
 
H-TdR, and
assaying 24 h later. The hybridomas were used to evaluate
whether mutant ras protein could be processed and presented by
APCs. In this assay, 10
 
5
 
 hybridoma cells and 7.5 
 
3
 
 10
 
5
 
 irradiated
syngeneic spleen cells were combined and cultured for 24 h with
either no antigen, 40 
 
m
 
g/ml peptide, or 40 
 
m
 
g/ml protein. Su-
pernatants were removed after 24 h and analyzed for IL-2. IL-2
released by the T cell hybridoma was measured by the growth of
IL-2–dependent CTLL cells using 3-(4,5-dimethylthiazol-2-yl),-2,
5 diphenyltetrazolium bromide (MTT; absorbance at 570 nm and
absorbance at 650 nm) as described (16, 18).
Delayed-type hypersensitivity (DTH) was measured 14 d after
immunization. The dorsal surface of each ear was injected with
10 
 
m
 
l containing 10–20 
 
m
 
g of peptide or saline alone using a 30-
gauge needle. Ear thickness was measured with precision spring-
loaded dial calipers (Mitutoyo; no. 7326, Precision Gage Co.) 24 h
after challenge. The averages of triplicate measurements were
compared with baseline measurements made immediately before
challenge injections.
 
ELISA for Measuring Anti-Ras Serum Antibody Titers. 
 
The ti-
ters of anti-ras antibody in the serum of mice immunized with
Arg
 
12
 
 ras peptide were measured using a modification of an
 
ELISA described previously (19). Mutant ras peptides (Arg
 
12
 
 and
Leu
 
61
 
) coupled to OVA or OVA alone and diluted in carbonate
buffer (pH 9.6) to a concentration of 3
 
 
 
m
 
g/ml were immobilized
in the wells of 96-well microtiter plates (no. 442404; Nalge Nunc
International) by overnight incubation at 4
 
8
 
C. Recombinant full-
length ras protein or control proteins (30 
 
m
 
g/ml) were similarly
immoblized. Microwells were washed once with distilled water
followed by three washes with PBS containing 0.05% Triton
X-100 (Sigma-Aldrich). Sera from control mice or mice immunized
with ras peptide were diluted in PBS containing 1% BSA (Sigma-
Aldrich; no. A7030). 50 
 
m
 
l were added to microwells containing
test or control antigens. Sera were incubated for 2 h at room tem-
perature, and the wells of the plates were washed as described
above. 50 
 
m
 
l of alkaline phosphatase–conjugated goat anti–mouse
antisera (BD PharMingen; no. 12063E) diluted 1:1,000 was added
to each well, and plates were incubated at room temperature for 1 h.
Plates were washed as described above, and 100 
 
m
 
l of 
 
p
 
-nitrophe-
nyl phosphate substrate (Sigma-Aldrich; no. N9389, 1 mg/ml dis-
solved in diethanolamine buffer) was added to each well. The re-
action was allowed to develop for 60 min at room temperature
before reading at dual wavelength (405 nm minus 650 nm) using
an ELISA reader (Molecular Devices).
 
Results
 
TGB6F1 Mice Respond to Immunization with the Arg
 
12
 
Mutant Ras Peptide. 
 
FVB mice, FVB6F1 mice, and the
Arg
 
12
 
 mutant ras transgenic TGB6F1 mice were immu-
Figure 1. FVB6F1 mice and cancer-prone TGB6F1 mice carrying a
mutant ras transgene mount a specific DTH response when immunized
against the mutant ras peptide, and lymphocytes from these mice mount a
specific proliferative response to the mutant peptide. (A) The proliferative
response of lymphocytes from immunized FVB, FVB6F1, and TGB6F1
mice was analyzed by harvesting draining LNCs 7–10 d after immuniza-
tion and pulsing them with 3H-TdR after 2 d of culture with or without
antigen, as indicated. Three representative experiments using cells taken
from a single or a pool of animals are shown. (B) DTH reactions were as-
sayed in TGB6F1 9-wk -old (Group 1)and 13-wk-old (Group 2) mice
that were naive or had been immunized with the Arg12 mutant ras pep-
tide in CFA or with saline in CFA. 14 d after the immunization, mice
were challenged with Arg12 mutant ras peptide in one ear and saline in
the other. The ear swelling was measured 24 h later. Bars represent SEM
of groups consisting of 10 mice. 
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nized in the footpads with the Arg
 
12
 
 mutant ras peptide in
CFA. LNCs from FVB6F1 mice immunized with Arg
 
12
 
mutant ras peptide responded when restimulated with the
Arg
 
12
 
 mutant ras peptide, whereas FVB mice, the strain of
origin of the TG.AC mice, did not respond (Fig. 1 A). The
magnitude of responses of cells from FVB6F1 mice was
similar to that of cells from C57BL/6 mice immunized
with the Arg
 
12
 
 mutant ras peptide (data not shown). LNCs
from mice immunized with adjuvant alone or with an un-
related antigen did not mount Arg
 
12
 
 mutant ras peptide–
specific proliferative responses (data not shown). Fig. 1 A
also shows that cells from TGB6F1 mice immunized with
Arg
 
12
 
 mutant ras peptide mounted specific proliferative re-
sponses to the peptide, indicating that tumor-free trans-
genic mice remained responsive to the immunogenic
mutant ras peptide sequence encoded by the inherited on-
cogene. Consistent with this finding is the fact that immu-
nized TGB6F1 mice also developed DTH to the Arg
 
12
 
mutant ras peptide (Fig. 1 B). Most importantly, TGB6F1
mice developed papillomas after promotion with PMA.
Thus, TGB6F1 mice were immunologically responsive to
Arg
 
12
 
 mutant ras peptide and were appropriate for deter-
mining the effect of immunization with Arg
 
12
 
 mutant ras
peptide on development of papillomas after promotion.
 
Preimmunization of TGB6F1 Mice with the Arg
 
12
 
 Mutant
Ras Peptide Enhances the Growth of Papillomas. 
 
12-wk-old
TGB6F1 mice (five per group) were immunized with the
Arg
 
12
 
 ras peptide in CFA, the Leu
 
61
 
 ras peptide in CFA, or
with CFA alone (time 0). Painting with the promoter be-
gan 3 wk after and ended 12 wk after the immunization.
Tumors began to appear near the end of PMA treatment,
and increased thereafter (Fig. 2 A). By week 13, four of the
five Arg12 mutant ras peptide–immunized mice had larger
tumors than mice immunized with Leu61 mutant ras pep-
tide in CFA or with saline in CFA (Fig. 3). Tumors in the
Arg12 mutant ras–immunized mice grew larger in the fol-
lowing weeks (Fig. 2 A), and differences between groups
increased (Fig. 2 B, left). This remarkable difference be-
tween the Arg12 mutant ras peptide–immunized mice and
the control groups was accounted for primarily by the
much larger average volume of the papillomas in the Arg12
mutant ras–immunized mice (Fig. 2 B, right), though the
number of papillomas was also marginally greater in the
Arg12 mutant ras–immunized group. The tumor volume
per mouse in the Arg12 mutant ras peptide–immunized
group increased more than fivefold during the following 5
wk (Fig. 2 A). By contrast, the papillomas in the control
groups remained about the same size or became smaller
Figure 2. Immunization against
a mutant region of the ras onco-
protein results in enhanced
growth of primary tumors in mice
carrying the mutant ras gene in
the germline. (A) Kinetics of tu-
mor development in relation to
immunization, DTH analysis, and
promotion. Chemical promotion
with PMA once every 3 d (20
treatments) was begun 3 wk after
and ended 11.7 wk after immuni-
zation. Five out of five Arg12 mu-
tant ras–immunized mice, five out
of five Leu61 mutant ras–immu-
nized mice, and three out of five
mice immunized with CFA devel-
oped two or more papillomas. (B)
The average total volume of tu-
mors per mouse and the average
volume of papillomas within each
group of mice. Tumor volumes in
B were measured 2.5 wk after the
end of PMA treatment. The num-
bers on top of the bars at left rep-
resent the average number of pap-
illomas per mouse within that
group. Five mice per group were
used. (C and D) The design of the
experiment and results were simi-
lar, except the experiment was
done  z1 yr later with 10 mice per
group. Tumor volumes in D were
measured 12.1 wk after the end of
the PMA treatment. 8/10 Arg12
mutant ras–immunized mice, 1/10
Leu61 ras–immunized mice, and 3/10 mice immunized with CFA alone developed two or more papillomas. The data in Fig. 2, A–D remain virtually
unchanged when all mice that developed no or only one papilloma after promotion are excluded as potential “nonresponders” (references 12, 13; de-
scribed in Materials and Methods).1949 Siegel et al.
during this time. The experiment was terminated at 20 wk
because of the large size of the tumors in four of the five
Arg12 mutant–immunized mice. Histologically, there was
no apparent difference between tumors from the Arg12 mu-
tant ras peptide–immunized mice and tumors in the control
groups at the time of killing. Clearly, the larger tumors in
the immunized groups were not due to increased inflam-
matory infiltrates (Fig. 4). The volumes of the 10 largest tu-
mors of the Arg12 mutant immunized group compared
with the volumes of the 10 largest tumors in either of the
control groups at 14, 17, or 20 wk were significantly larger
(P , 0.001) at each of the three time points. There were
no significant differences between the control groups.
The experiment was repeated using newly synthesized
batches of peptide reagents. Because some older mice spon-
taneously develop jaw and other non-skin tumors (2, 6),
separate groups of 13-wk-old and 9-wk-old mice (10 per
group) were compared. Both groups of mice immunized
with the Arg12 mutant ras peptide and challenged with the
Arg12 mutant ras peptide had DTH reactions, whereas mice
immunized with CFA alone did not, showing as in previ-
ous experiments that the mice were not tolerant to the pep-
tide. Mice immunized with Leu61 mutant ras peptide and
challenged with the Leu61 mutant ras peptide had weak re-
sponses that were less specific for the Leu61 mutant ras pep-
tide (data not shown). 1 wk after testing for DTH, promo-
tion began. Tumors started to appear after cessation of
promotion (Fig. 2 C), and from week 14 on, tumor vol-
umes per mouse were much larger (.18-fold) in the Arg12
mutant ras–immunized group than in the control groups
(Fig. 2 D, left). As observed earlier, this difference was due
to an increased average volume of the papillomas in the
Arg12 mutant ras–immunized mice (Fig. 2 D, right). The
results for older and younger mice were comparable (data
not shown).
Mice Immunized with the Arg12 Mutant Ras Peptide Respond
Preferentially to the Arg12 Peptide and Not to the Intact Arg12
Mutant Ras Oncoprotein.  We next sought evidence that
CD41 T cells specific for Arg12 mutant ras and induced by
immunization with this peptide indeed responded to the in-
tact protein produced by tumor cells. Thus, we immunized
mice with the Arg12 mutant ras peptide and analyzed the re-
sponse of these T cells to peptide or the intact protein. Fig.
5 (top) shows that the LNCs from these mice responded
preferentially to the peptide in repeated experiments. This
Figure 3. Enhanced tumor development in TGB6F1 mice with the Arg12
mutant ras peptide. Five mice per group were immunized with the Arg12 mu-
tant ras peptide in CFA, the Leu61 mutant ras peptide in CFA, or with saline in
CFA. Pictures were taken 1.5 wk after the end of promotion (mice anesthe-
tized for photography). Although the difference between the specifically
immunized and the control groups is apparent, the bottom panel shows that
papillomas developed more slowly in one of the five Arg12 mutant ras peptide–
immunized mice, and some of the papillomas in the Arg12 mutant ras of the
other four similarly immunized group remained small. The results shown here
and in Fig. 2, A and B are derived from the same experiment; pictures shown
here were taken 1 wk earlier than results shown for the same mice in Fig. 2 B.
Figure 4. Photomicrograph
illustrating the appearance of a
papilloma on the back skin of an
Arg12 mutant ras–immunized
mouse at time of sacrifice. The
lower magnification (original
magnification:  320) shows the
keratinization of the papilloma.
At the higher magnification
(original magnifications: 3100
and 3200), the dysplastic epithe-
lial changes and the neutrophilic inflammatory infiltrate at the epidermal–dermal interphase become evident. These inflammatory infiltrates do not con-
tribute significantly to the tumor volume and are similarly found in papillomas of control mice (not shown). Hematoxylin and eosin staining.1950 Enhanced Primary Tumor Growth after Immunization to a Mutant Oncoprotein
predominant response pattern is also reflected in T cell hy-
bridomas derived from T cells of Arg12 mutant ras peptide–
immunized mice by fusion with BW5417 cells (Fig. 5, mid-
dle and bottom). However, lysates of several Arg12 mutant
ras protein–expressing tumor cells failed to stimulate specif-
ically the hybridoma in the presence of APCs. More sur-
prisingly, the T cell line and the hybridoma even failed to
respond specifically to lysates of cells that had been infected
with Arg12 mutant ras vaccinia virus, and were expressing
large amounts of the Arg12 mutant ras protein (data not
shown). We then generated large amounts of affinity-puri-
fied recombinant Arg12 mutant ras protein. However, the
hybridoma also did not respond to this protein in the pres-
ence of APCs (Fig. 4, right). These results suggested that
when the intact Arg12 mutant ras protein was available for
exogenous presentation, the antigen was not recognized by
the Arg12 mutant ras–specific CD41 T cells (19).
This response pattern was confirmed with a second hy-
bridoma derived from another T cell line, 2F9 (8), which
also originated from LNCs of Arg12 mutant ras peptide–
immunized mice. Fig. 5 (middle and bottom) shows that the
2F9-derived hybridoma also failed to respond to the puri-
fied protein we had made. Interestingly, we observed a re-
sponse to a recombinant Arg12 mutant ras protein that had
been purified in another laboratory by gel filtration (20).
These differences are likely due to the substantially differ-
ent purification procedures. We used affinity purification:
the NH2-terminal immunogenic portion of the ras protein
will only be found in the purified fraction if it was part of
the complete protein that contained the COOH-terminal
end that binds to the affinity column (discussed in Materials
and Methods). This is important because recombinant pro-
tein preparations from bacteria are likely to contain protein
fragments and unfolded proteins because of the action of
bacterial endopeptidases. Indeed, Fig. 6 shows that the af-
finity-purified Arg12 mutant ras protein, when cut with the
bacterial endopeptidase (Glu-C), was as stimulatory of the
anti-Arg12 mutant ras hybridoma as the mutant peptide (us-
ing equimolar concentrations). Undigested highly purified
protein failed to show any stimulation, even at the highest
concentrations used. The bacterial endoproteinase, Glu-C,
would be expected to cut the mutant ras protein at
glutamic acid residues at positions 3 and 31, thereby releas-
ing an immunostimulatory 28-mer oligopeptide. Together,
our results suggest that the CD41 T cells predominantly in-
duced by immunization with the Arg12 mutant ras peptide
were specific for this peptide and could not recognize the
intact mutant protein that is produced by tumor cells in the
presence of APCs.
Mice Immunized with Arg12 Mutant Ras Peptide Produce
Antibodies that Bind Arg12 Mutant Ras Protein.  In prelim-
inary experiments, C57BL/6 mice immunized with the
fied (Affin.) Arg12 mutant ras protein was prepared from a recombinant
GST fusion protein as described. The ion exchange (Ion-ex.) matrix–
purified Arg12 and Leu61 mutant ras proteins were a gift from Dr. R.G.
Fenton. The average of duplicate samples are shown. Wt, wild-type.
Figure 5. Arg12 mutant ras peptide is preferentially recognized by T
cells from mice immunized with the Arg12 mutant ras peptide or by T hy-
bridoma cells derived from these T cells. Top: proliferative response of
LNCs in vitro from mice immunized with Arg12 mutant ras peptide, and
with CFA 9 d earlier. Three representative experiments using cells taken
from a single or pool of animals are shown. Mutant L26 (MutL26) protein
is used as a control. Middle: proliferation of an anti-Arg12 mutant ras T
cell line when cultured with the Arg12 mutant ras peptide (left). T cell hy-
bridoma derived from this T cell line remains Arg12 mutant ras peptide
specific, but does not respond to the Arg12 mutant ras protein (right).
Cells from the T cell line or T cell hybridoma were cultured with anti-
gen, and spleen cells were provided as APCs. The antigen-specific stimu-
lation of the T cells caused increased 3H-TdR incorporation, whereas the
antigen-specific stimulation of the T cell hybridoma caused IL-2 release,
which was analyzed using growth stimulation of the IL-2–dependent
CTLL cells as determined by a colorimetric assay (described in Materials
and Methods). Bottom: same as top, except a different T cell line 2F9 (8)
was used. This T cell line 2F9 is also specific for the Arg12 mutant ras pep-
tide, and the T cell hybridoma derived from this T cell line again only
recognizes the mutant peptide and not the intact protein. Affinity-puri-1951 Siegel et al.
Arg12 mutant ras peptide in CFA followed by multiple
boosts with the peptide in IFA produced significant titers of
Arg12 mutant ras peptide–specific antibodies. There was no
measurable cross-reactivity with the Leu61 mutant ras pep-
tide (data not shown). We then immunized four TGB6F1
mice with the Arg12 mutant ras peptide in CFA followed
by two booster immunizations with the peptide in IFA. All
four F1 mice produced antibodies that bound the Arg12
mutant ras peptide (Fig. 7, left). Importantly, sera from all
four of the TGB6F1 mice immunized with the Arg12 mu-
tant ras peptide also contained antibodies that bound the
intact Arg12 mutant ras protein (Fig. 7, middle). None of
the antisera contained antibodies that bound more effec-
tively than control serum to L26, an unrelated control pro-
tein purified by the same procedure and used at similar
concentrations for coating the ELISA plates (Fig. 7, right).
These results were confirmed and extended by immu-
nizing TGB6F1 mice once (without boost) with the Arg12
mutant ras peptide or Leu61 mutant ras peptide (four mice
per group) followed by promotion (Fig. 8 A). Sera from all
four Arg12 mutant ras peptide–immunized mice taken 7 wk
after the end of promotion contained Arg12 mutant pep-
tide–specific antibodies (Fig. 8 B, left panels), whereas none
of the four Leu61 mutant peptide–immunized mice had an-
tibodies that bound either peptide (data not shown). Sera
from two of the four Arg12 mutant ras peptide–immunized
mice had high titers of antibody against intact Arg12 mutant
ras protein, but none of the sera contained antibodies
against an unrelated protein purified by the same proce-
dures (Fig. 8 B, right panels). Remarkably, the two mice
that had serum antibodies against the protein also had large
tumors, whereas the two mice in the group that had failed
to develop Arg12 mutant ras protein–binding antibodies
failed to develop a significant tumor load (Fig. 8 B, right
panels). Furthermore, the two mice immunized only once
followed by promotion and tumor development had higher
titers against the mutant protein than the mice in the previ-
ous experiment, which had been immunized multiple
times but not promoted, and which remained tumor free.
(Compare titers of serum of the singly immunized, pro-
moted, tumor-bearing mouse no. 2 with titers of the other
four sera obtained from three-times immunized, not pro-
moted, tumor-free mice in Fig. 6).
Discussion
Immunizing cancer-prone mice with peptide corre-
sponding to the mutant region of an oncoprotein led to
markedly enhanced tumor growth in most mice. Immuni-
zation with the Arg12 mutant ras peptide did not induce T
cell tolerance, as T cells from immunized mice proliferated
in vitro when stimulated by the mutant peptide, and im-
munized mice had DTH to the peptide in vivo. Although
T cells induced by immunization with the mutant ras pep-
tide responded predominantly to the peptide and not to the
intact mutant ras oncoprotein, this immunization did stim-
ulate the production of antibodies that bound the mutant
ras protein. In a single small experiment, the serum titers
corresponded directly to the tumor burden.
Many years ago, Peyton Rous and his coworkers recog-
nized that tumors develop from “subthreshold neoplastic
states” (21, 22; now referred to as the initiation stage) and
that wounding could trigger tumorigenesis (now referred
Figure 6. The mutant Arg12 ras peptide and digests of the Arg12 mutant
ras protein but not the intact protein stimulate Arg12 mutant ras peptide–
specific T hybridoma cells. Equimolar concentrations of either the Arg12
mutant ras peptide, the undigested protein, or protein digested by expo-
sure to the bacterial endoprotease Glu-C were tested for antigen-specific
stimulation of hybridoma R12-H2 derived from the 2F9 T cell line. An-
tigen recognition by the hybridoma cells resulted in IL-2 release, which
was analyzed using growth stimulation of the IL-2–dependent CTLL cells
in a colorimetric assay. Proteins were prepared and digested as described
in Materials and Methods.
Figure 7. TGB6F1 mice immunized repeatedly with the Arg12 mutant
ras peptide produce Arg12 mutant ras peptide–specific antibodies, and
some of these antibodies also recognize the intact protein specifically.
Mice were immunized intraperitoneally with 100 mg of the Arg12 or
Leu61 mutant ras peptide in CFA and boosted twice at 2-wk intervals
with the peptide in IFA. 2 wk after the last boost, sera from immunized
mice were tested for antibodies specific for mutant ras peptide or protein.
Sera of all four mice have antibody that binds mutant ras peptide and also
the mutant ras protein, but the antibodies did not bind a control protein.
For comparison, the serum of mouse no. 2 (d), which was immunized
only once (1x) with the Arg12 mutant ras peptide in CFA and then pro-
moted with PMA followed by development of papillomas, was included.
This serum is identical to that of mouse no. 2 (d) shown in the middle
panel. 3x, three times.1952 Enhanced Primary Tumor Growth after Immunization to a Mutant Oncoprotein
ing the parental cancer-prone transgenic FVB strain, about
one third of mice with persistent papillomas developed ma-
lignant skin cancers 6–12 mo after cessation of the PMA
treatment (2), a much longer period than one could have
reasonably kept the immunized mice with large papillomas.
Very few papillomas regressed in the Arg12 mutant ras pep-
tide–immunized mice, whereas papillomas in the control
groups remained very small. Papillomas that regress after
promotion are called promoter dependent, whereas papil-
lomas that persist are called promoter independent (24).
The papillomas of specifically immunized as well as control
mice had persistent, i.e., promoter-independent papillo-
mas. Presumably because of the much more rapid growth
of papillomas in the specifically immunized group, the risk
of these papillomas becoming malignant is increased be-
cause of the continued clonal expansion of the initiated cell
population with the increased probability of additional mu-
tations necessary for progression to malignancy. However,
it is unclear how immunization against the mutant peptide
led to increased proliferation and large papillomas. But re-
gardless of the mechanism, increased proliferation appears
to be the important and common mechanism whereby a
wide variety of injuries, infections, hormones, growth fac-
tors, and chronic inflammation enhance the development
of cancers in various organs such as bowel, liver, esophagus,
breast, gall bladder, oral cavity, and skin (for a review, see
reference 23).
We have not found published evidence that active im-
munization against an antigen expressed by initiated cells
can lead to enhanced growth of primary tumors, but an im-
mune stimulation of tumor growth has been postulated for
decades (25). It has been postulated that vaccination leading
to a “weak” immune reaction might stimulate rather than
inhibit the growth of primary tumors (26). In the case of
hepatitis B virus–mediated hepatocarcinogenesis, it is pos-
tulated that a strong T cell response can eradicate the virus
from the host, whereas a response too weak to terminate
the infection is procarcinogenic (27). Presumably a particu-
lar type of chronic inflammation caused by a weak response
stimulates hepatocellular proliferation and the enhanced
development of hepatocellular cancers. In our model, vac-
cination of cancer-prone mice with the Arg12 mutant ras
peptide (26) failed to induce detectable destructive T cell
responses, but did induce antibody responses to the mutant
protein. Whether the immunological mechanism(s) re-
sponsible for the enhanced tumor growth is related to anti-
body itself and/or to alterations (e.g., cytokine milieu) in-
herent in hosts mounting an antibody response is not
known. Interestingly, the level of specific antibody corre-
sponded with the total volume of the papillomas in the four
mice we tested, but a much larger group will have to be
studied, and it will be interesting to determine the sub-
classes of the mutant ras protein–binding antibodies in mice
developing tumors. We are in the process of backcrossing
the TG.AC mice to mice lacking mature B cells to deter-
mine whether B cells and/or antibody play a central role in
the observed enhancement.
Induction of a humoral response against the extracellular
Figure 8. TGB6F1 mice immunized only once but then promoted
with PMA can produce antibody specific for Arg12 mutant ras peptide,
and antibody titers correlate directly with tumor burden. (A) Experimen-
tal design and kinetics of tumor growth. TGB6F1 mice were immunized
with 150 mg of either Arg12 or Leu61 mutant ras peptide in CFA (four
mice per group) and then promoted with PMA as described in Materials
and Methods. Kinetics of tumor development and time of serum sam-
pling in this group is indicated. (B.) Sera of all of the four TGB6F1 mice
singly (1x) immunized with the Arg12 mutant ras peptide and then pro-
moted with PMA have antibody that binds Arg12 mutant ras peptide and
not the Leu61 mutant ras peptide, but only antibodies in sera of mice nos.
2 and 4 also bind mutant ras protein. These antibodies were Arg12 mutant
ras protein specific because they did not bind to the L26 control protein.
Protein binding antibody titers correlated with the host tumor burden.
Numbers in the rectangles represent total tumor volume in mm3 for the
indicated mouse at the time the serum was taken. Sera from Leu61 mutant
peptide–immunized mice do not have antibodies that bind either ras pep-
tide (data not shown).
to as promotion). Subsequent work showed that various
chemicals and inflammatory states can promote tumor de-
velopment (for a review, see reference 23). This appears to
be the first published report that active immunization can
cause the enhanced growth of primary tumors.
Because the Arg12 mutant ras peptide–immunized mice
developed large tumor burdens, they were killed before
obvious malignant lesions developed. In an earlier study us-1953 Siegel et al.
domain of the HER2/neu growth factor receptor can re-
duce primary mammary tumor development in transgenic
mice, but antibody-mediated downregulation of the recep-
tor appears to be the mechanism (28). In previous studies,
Ig actively produced or passively given enhanced growth of
tumor grafts (29–31), and malignant tumors grew more
slowly or were rejected by mice unable to produce Ig (32,
33). Also, mice with low Ig responses are more resistant to
chemically induced tumorigenesis (34, 35). Several mecha-
nisms have been postulated by which Ig or B cells secreting
Ig may enhance tumor growth: (a) by blocking epitopes
that are required for tumor rejection (36), (b) by suppress-
ing activation and/or proliferation of tumor-specific CTLs
by TGF-b carried by IgG (37, 38) (consistent with such a
mechanism is the finding that conditions leading to strong
antibody responses appear to inhibit CTL induction; refer-
ence 39), and (c) by antitumor antibody–tumor antigen
complexes formed in and around tumors, which may alter
inflammation and angiogenesis as well as have other effects
(23). Also, actively growing papillomas in the tumor-prone
mice are surrounded by conspicuous cellular inflammatory
infiltrates (40), and B cells in such infiltrates may downregu-
late the production of IFN-g and IL-12 (41). This is of in-
terest because mice deficient in IFN-g signaling are sensi-
tive to tumor development (42, 43), particularly when the
mice carry a mutant Harvey ras gene (as is the case here) or
are nullizygous for p53. We have preliminary data indicat-
ing that neutralizing endogenous IFN-g in vivo in our
model enhances papilloma growth (Schreiber, K., R.D.
Schreiber, and H. Schreiber, unpublished data). Thus, we
are currently exploring whether active immunization may
result in reduced endogenous IFN-g production.
Mutant ras proteins should be ideal candidate antigens
that are not only cancer-specific but are also shared by can-
cers from different individuals. For example, one of three to
four different single amino acid substitutions in codon 12 of
the cellular Kirsten ras gene is found in .90% of pancreatic
cancers (44). Based upon the amino acid sequences en-
coded by these mutant ras genes, candidate peptides for im-
munotherapeutic trials have been designed that bind to
MHC molecules and induce T cell responses, a strategy for
selecting epitopes referred to as “reverse immunology”
(45). CD41 and CD81 T lymphocytes that recognize point
mutations in ras have been described in mice and humans
after immunization in vitro and in vivo. In one model using
mice immunized with mutant ras oncoprotein, preventive
as well as therapeutic effects against transplanted tumor cells
transfected to overexpress ras have been reported (20, 46).
Thus, certain mutant ras oncoproteins may be useful as
shared yet tumor-specific antigens.
Nevertheless, these studies had certain problems. (a)
MCA-induced tumors have antigens that can lead to the
rejection of transplanted tumor cells; however, the tumor-
rejection antigens appear to be unrelated to the mutant ras
protein that these tumors express (47). (b) Studies in mice
that reported the induction of CD81 T cells and protective
or therapeutic effects used malignant cell lines that had been
transduced to overexpress the mutant ras gene rather than
using unmanipulated tumors expressing mutant ras (20, 48–
51). At present, there is no convincing evidence that unma-
nipulated tumor cells spontaneously expressing mutant ras
at transforming levels would be susceptible targets for de-
struction by ras-specific immune responses. (c) Studies in
humans also failed to demonstrate antitumor effects against
unmanipulated (untransfected) tumor cells (50, 52), al-
though in one recent study, almost 20% specific lysis of tu-
mor cells expressing the appropriate mutant ras protein was
achieved; even this low level of lysis required that the tu-
mor targets be pretreated with IFN-g (53). (d) Although
numerous studies in humans and mice have demonstrated
the induction of CD41 T cells specific for mutant ras pep-
tides (53–65), none of these studies have demonstrated re-
stimulation of these T cells by unmanipulated lysates of un-
transfected tumor cells expressing an endogenous mutant
ras protein. Insufficient amounts of antigen or inefficient
antigen presentation may be a problem, as a recent study
showed restimulation of CD41 T cells by detergent lysates
of human tumor cells extracted and enriched for the mutant
ras protein by antibody-coated plates (53). (e) None of the
previous studies (8, 54, 56–58) used affinity-purified pro-
tein for the induction or restimulation of mutant ras–spe-
cific CD41 T cells, and the preparations of recombinant
proteins purified by ion exchange and gel filtration are
likely to have contained peptide fragments because of con-
tamination with bacterial endopeptidases. At present, we do
not know whether simply unfolding of the protein by non-
ionic detergent (50) or whether complexes of antibody and
antigen (53) can allow mutant ras protein to be presented
more effectively on MHC class II molecules by the endog-
enous lysosomal pathway.  However, the endogenous anti-
gen-presenting pathway does not seem to provide the Arg12
mutant ras peptide, as tumor cells expressing the mutant ras
protein as well as the restricting MHC class II molecule af-
ter transfection were very poor targets for mutant ras pep-
tide–specific CD4+ T cells in a 51Cr-release assay, unless the
appropriate mutant ras peptide had been added exoge-
nously (66). Similarly, L cells expressing the restricting
MHC class II molecule after transfection and the mutant ras
protein after infection with recombinant mutant ras vac-
cinia did not stimulate the CD41 T cell hybridoma in vitro
unless the mutant ras peptide had been added exogenously
(Siegel, C., and H. Schreiber, unpublished results). It
would be interesting to determine the peptides that are pre-
sented by the MHC class II molecules of APCs after pro-
cessing of the intact mutant ras protein. The peptide-induced
T cells must recognize conformations of the peptide that
are not or are deficiently produced by APCs processing the
intact protein. In any case, immunization with the mutant
ras protein may induce a T cell response capable of recog-
nizing the protein more effectively (67).
Stimulating immunity that protects against the develop-
ment of cancer has many difficulties. Somatic or germline
mutations in oncogenes or suppressor genes that lead to
cancer usually consist of single amino acid substitutions or
fusions of two different proteins. Because the gene prod-
ucts are, except for the fusion point or point mutation,1954 Enhanced Primary Tumor Growth after Immunization to a Mutant Oncoprotein
identical to normal cellular self-proteins, neonatal and/or
peripheral tolerance to the nonmutant portions of these
proteins must limit the number of new epitopes produced.
Therefore, an immune response is likely to be limited to
the small region containing the point mutation or the junc-
tion of fused self-proteins. By contrast, in the case of viral
or xenogeneic proteins, using conditions at which no nor-
mal cellular homologues of the transgenes are expressed
during and after ontogeny, the entire protein can poten-
tially serve as a source for antigenic peptides. Such strong
immunogenicity may explain why active immunization or
adoptively transferred T cells are effective in preventing de-
velopment of primary cancers expressing the simian virus
40 T antigen as a transgene (5, 68, 69).
Our data showing that immunization with a mutant ras
peptide led to increased tumor growth raise several intrigu-
ing but as yet unanswered questions. It is not known
whether immunization with intact ras protein would have
conferred protection against tumor growth in these ani-
mals. The potential role of antibody in promoting tumor
growth in the mutant ras peptide–immunized animals also
needs to be elucidated further. As discussed above, B cells
and/or Ig may be involved in tumor/graft enhancement,
but it is not clear whether the underlying mechanism is
mediated by B cells and/or Ig itself, by B cells and/or Ig
suppressing T cell responses, and/or by alterations in host
cells and cytokine production which accompany B cell re-
sponses. Nevertheless, whatever the answers may be, our
result raise an important cautionary note. Clinical trials
have begun in patients bearing mutant ras–expressing can-
cers by active immunization with mutant ras peptides (59,
70). Our results suggest that, in the absence of an effective
T cell response to the mutant proteins, active immuniza-
tion of cancer-prone or cancer-bearing individuals may
enhance development and/or growth of cancers, and
therefore immunization by certain procedures may be
contraindicated. However, our results also show that an
immune response to a cancer-specific peptide can pro-
foundly and substantially perturbate the development of
primary tumors in mice. Inducing a different type of im-
munity might confer protection against tumor develop-
ment.
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